Shares of this smallcap health care company gained 5.07 percent when the company reported robust growth in Q2FY24 with profit increasing by 70 percent. The company has a market capitalization of Rs. 3,199.21 crores.
At 11:21, 8th November shares of Yatharth Hospital & Trauma Cre Srvcs Ltd were trading at Rs. 393.65 per share, up by 5.07 percent from previous closing price of Rs. 374.65 per share. The stock has delivered 17.91 percent returns in the last 6 months.
Such bullish stock price movements were observed after the company announced results for Q2FY24 and reported 70 percent profit growth to Rs. 276 crores from Rs. 162 crores on yearly basis. Moreover, revenue growth of 34 percent was witnessed and the company reported PAT margins increase by 345 bps to 16.1 percent compared to the same quarter of previous financial year.
Looking at the profitability ratios, the company reported return on equity (ROE) of 43.87 percent and return on capital employed (ROCE) of 26.88 percent in the last financial year.
The company’s promoters possess roughly 66.33 percent of the shares, while the public owns 19.37 percent with the direct institutional investors (DIIs) holding about 8.8 percent leaving the remaining 5.42 percent shares with the foreign institutional investors (FIIs).
Established in 2008, Yatharth Hospital and Trauma Care Services Limited is a multi-care hospitals in Noida, Greater Noida, and Noida Extension, Uttar Pradesh providing a wide spectrum of super speciality services in the field of cardiology, neurology etc.
Written by: Vinit Israni
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
